VLDL cholesterol measurement

Known as: very low density lipoprotein (VLDL) level test, VLDL Cholesterol, Very Low Density Lipoprotein Cholesterol Measurement 
The determination of the amount of very low-density lipoprotein cholesterol present in a sample.
National Institutes of Health

Related topics

Related topics

4 relations
CDISC SDTM Laboratory Test Terminology by CodeCDISC SDTM Laboratory Test Terminology by NameClinical Data Interchange Standards Consortium Terminology

Broader (1)

Very low density lipoprotein

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
OBJECTIVE Associated with insulin resistance in type 2 diabetes are increased serum triglycerides, decreased HDL cholesterol, and… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2007
2007
The prime role of HDL to transport lutein into the retina: evidence from HDL-deficient WHAM chicks having a mutant ABCA1 transporter.
PURPOSE Lutein and zeaxanthin are largely transported in plasma by high-density lipoprotein (HDL). The Wisconsin hypoalpha mutant… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2004
Review
2004
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Reduction of low-density lipoprotein cholesterol (LDL-C) is presently the primary focus of lipid-lowering therapy for prevention… (More)
Is this relevant?
Review
2002
Review
2002
Diabetic dyslipidemia.
By the year 2025, there will be more than 300 million type 2 diabetes sufferers worldwide. This epidemic will be followed by a… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.
BACKGROUND Plasma triglyceride concentration has been an inconsistent independent risk factor for coronary heart disease, perhaps… (More)
  • table 1
  • table 2
  • table 3
  • table 3
  • figure 1
Is this relevant?
2000
2000
Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin.
Appearance, pharmacokinetics, and distribution of astaxanthin E/Z and R/S isomers in plasma and lipoprotein fractions were… (More)
  • figure 3
  • table 1
  • figure 4
  • figure 5
Is this relevant?
Review
1998
Review
1998
Lipoprotein physiology.
Lipoproteins are spherical macromolecular complexes in which hydrophobic molecules of triglyceride and cholesteryl ester are… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis.
Increased plasma cholesterol, particularly that portion associated with LDL, is an established risk factor for coronary heart… (More)
  • table 1
Is this relevant?
1997
1997
Acute in vitro production of acylation stimulating protein in differentiated human adipocytes.
We have previously shown that in normolipidemic healthy adults, plasma acylation stimulating protein (ASP) increases… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment
Cholesterol absorption and metabolism and LDL and HDL kinetics were investigated in 11 hypercholesterolaemic non-insulin… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?